← Leaderboards
Martin J Edelman
University Of Maryland Baltimore
$983,676
Attributed
$983,676
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $283.1K · FY2009–11$500K$375K$250K$125K$0
'09
'10
'11
Funding mix
By agency
NIH$983,676 · 4
By mechanism
R21$527,119 · 1
U01$371,938 · 1
U10$71,489 · 1
M01$13,130 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Shiraz I Mishra$5,337,916
- Peter W Melera$696,268
- David A Van Echo$199,808
- Stephen C Jacobs$744,798
- Huang Chiao Huang$6,185,360
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationResponseBaseDoseToxic EffectClinical ResearchCell ProliferationClinical Trials DesignCancer EtiologyAlkylating AgentsCell DeathAntineoplastic AntibioticsCisplatinCessation Of LifeCancer PatientBinding (Molecular Function)Cancer CellArsenicalsBioavailableBiologicalBiomarkerAffectAdvanced DiseaseArchives
Grant awards (6)
Telemere Targeted Therapy in Lung Cancer$257,185
R21 · FY2011 · CA · contact PI
Telemere Targeted Therapy in Lung Cancer$1
R21 · FY2010 · CA · contact PI
Telemere Targeted Therapy in Lung Cancer$269,933
R21 · FY2009 · CA · contact PI
CLINICAL TRIAL: EVALUATION OF MAGE-A3/HPV 16 TROJAN PEPTIDES IN SCCHN$13,130
M01 · FY2009 · RR · contact PI
PHASE I TRIALS OF ANTICANCER AGENTS$371,938
U01 · FY2002 · CA
CANCER AND LEUKEMIA GROUP B$71,489
U10 · FY2002 · CA